Effect of dorzolamide/timolol combination on the visual field in glaucoma

Código QR

Effect of dorzolamide/timolol combination on the visual field in glaucoma

Sakurako Takeda,1,2 Tatsuya Mimura,1 Masao Matsubara1,2 1Department of Ophthalmology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Department of Ophthalmology, Nippori Clinic, Medical Center East, Tokyo Women’s Medical University, Tokyo, Japan Purpose:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeda S, Mimura T, Matsubara M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/63ac0c431aad4a47951983cd5d376d04
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
por: Takeda S, et al.
Publicado: (2014)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Rational use of the fixed combination of dorzolamide &ndash; timolol in the management of raised intraocular pressure and glaucoma
por: Jason Yeh, et al.
Publicado: (2008)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Nicholas P Bell, et al.
Publicado: (2010)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini R, et al.
Publicado: (2015)

A patient preference comparison of Azarga&trade; (brinzolamide/timolol fixed combination) vs Cosopt&reg; (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Thomas K Mundorf, et al.
Publicado: (2008)

Patient perspectives when switching from Cosopt&reg; (dorzolamide-timolol) to Azarga&trade; (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger GA, et al.
Publicado: (2012)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama Y, et al.
Publicado: (2015)

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension
por: Cindy Hutnik, et al.
Publicado: (2010)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
por: Seibold LK, et al.
Publicado: (2014)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Moisseiev E,&nbsp;Lazar M, et al.
Publicado: (2012)

Patient satisfaction with glaucoma therapy: reality or myth?
por: Lemij HG, et al.
Publicado: (2015)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Yoshimi Nakamura, et al.
Publicado: (2009)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe NM
Publicado: (2014)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
por: Kenji Inoue, et al.
Publicado: (2011)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa K, et al.
Publicado: (2014)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo O, et al.
Publicado: (2015)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
por: Yoshikawa K, et al.
Publicado: (2014)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue K, et al.
Publicado: (2015)

Progressive retinal detachment secondary to juxtapapillary microholes in association with type 3 posterior staphylomas
por: Dinah CB, et al.
Publicado: (2014)

Combined Baerveldt glaucoma drainage implant surgery and surgical bleb revision for preventing a postoperative hypertensive phase
por: Kawai M, et al.
Publicado: (2014)

Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients
por: Cordeiro MF, et al.
Publicado: (2015)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients
por: Adam M Moss, et al.
Publicado: (2010)

Visual and optical performance of diffractive multifocal intraocular lenses with different haptic designs: 6 month follow-up
por: Wang M, et al.
Publicado: (2014)

The early history of glaucoma: the glaucous eye (800 BC to 1050 AD)
por: Leffler CT, et al.
Publicado: (2015)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development
por: Agarwal A, et al.
Publicado: (2015)

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
por: Chavan R, et al.
Publicado: (2014)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses
por: Nagahara Y, et al.
Publicado: (2015)

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
por: Contreras-Salinas H, et al.
Publicado: (2021)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed MF, et al.
Publicado: (2011)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Anne J Lee, et al.
Publicado: (2008)

A case of WAGR syndrome in association with developmental glaucoma requiring bilateral Baerveldt glaucoma implants and subsequent tube repositioning
por: Akagi T, et al.
Publicado: (2015)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
por: Tsumura T, et al.
Publicado: (2015)